Active Implants LLC

FDA Rejected Neuralink’s Plans For Human Trials In 2022, Reuters Reports The US Food and Drug Administration rejected Neuralink Corp. ’s plans for a human clinical trials of its Link brain interface

Active Implants LLC is ramping up for a 2019 commercial launch of its NUsurface polycarbonate-urethane meniscus implant, outside the US, as it continues clinical trials in the US. It hopes to file

Device Transactions Financing by device companies in the first quarter of 2017 totaled $2.3 billion, slightly lower than Q4 2016's $2.4 billion. Notably, early-stage venture capital fundraising made u

Company Changes ADAMS , Derek, PhD To: bluebird bio Inc. , Chief Technology & Mfg. Officer (March) From: Evelo Biosciences, SVP, CMC Phone: 339-499-9300 ARBET-ENGELS , Christophe, MD, PhD To: